GARY S JACOB

CIK 1266802 · CHIEF DEVELOPMENT OFFICER · last filed 2026-07-23

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$202.3K

Companies

10

Total Filings

55

Lifetime Open-Market Net

$163.3K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OKYO CHIEF DEVELOPMENT OFFICER 112,420 $1.64 $184.4K $50.0K 2 2026-07-23
Hepion Pharmaceuticals, Inc. (HEPA) Delisted Director 12 $0.08 $1 $19.9K 6 2024-02-21
Virpax Pharmaceuticals, Inc. (VRPX) Delisted Director 14 $0.00 $0 $23.8K 3 2022-01-05
CRDF Director 21,922 $0.82 $17.9K $49.7K 4 2021-06-15
Cardiff Oncology, Inc. (TROV) Delisted Director 148,954 $0 5 2019-06-24
Hepion Pharmaceuticals, Inc. (CTRV) Delisted Director $0 2 2018-07-03
SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted Executive Chairman 595,460 $20.0K 4 2018-06-18
Cardiff Oncology, Inc. (TROVW) Delisted Director $0 7 2017-01-05
SYNERGY PHARMACEUTICALS, INC. (SGYPW) Delisted Chief Executive Officer 396,999 $0 13 2016-06-27
CALLISTO PHARMACEUTICALS INC (KAL) Delisted Chief Executive Officer 1,474 $1.12 $1.7K $0 2 2007-10-25

Recent Filings · Page 2 of 6

55 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-08-21 Hepion Pharmaceuticals, Inc. (HEPA) Delisted Grant (A) $0 EDGAR
2020-06-19 CRDF Grant (A) $0 EDGAR
2020-05-18 CRDF Buy (P) +17,483 $25.0K EDGAR
2020-04-07 Hepion Pharmaceuticals, Inc. (HEPA) Delisted Grant (A) $0 EDGAR
2019-07-25 Hepion Pharmaceuticals, Inc. (HEPA) Delisted Grant (A) $0 EDGAR
2019-06-24 Cardiff Oncology, Inc. (TROV) Delisted Grant (A) $0 EDGAR
2018-07-03 Hepion Pharmaceuticals, Inc. (CTRV) Delisted Buy (P) $0 EDGAR
2018-06-18 SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted Mixed +192,781 $237.5K EDGAR
2018-01-25 Cardiff Oncology, Inc. (TROV) Delisted Grant (A) $0 EDGAR
2018-01-09 SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted Grant (A) $0 EDGAR
Showing 1120 of 55
Page 2 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.